BP1.15205 is a differentiated chemical scaffold, demonstrating high potency and selectivity in preclinical studies with a favorable safety profile and the potential for once-daily dosing Topline clinical data expected in 2026 PLYMOUTH MEETING, Pa. / Nov 19, 2025 / Business Wire...Read more
Topline data expected in first quarter of 2026 Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, Nov. 19, 2025 /PRNewswire/...Read more
80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical success Clinical success achieved with one or two doses of TARA-002 in 88% of patients TARA-002 demonstrated favorable safety and tolerability...Read more
NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted...Read more
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more personalized patient care TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE...Read more
Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy Underscores IMDELLTRA as a Recognized Standard of Care Treatment for Patients With Extensive Stage Small Cell Lung Cancer That Has Progressed THOUSAND OAKS, Calif., Nov. 19,...Read more
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| IDEXX Laboratories | 26.89 4.01 | $697.10 |
| Eli Lilly | 19.55 1.90 | $1,049.60 |
| Intuitive | 17.87 3.27 | $564.64 |
| Exact Sciences | 16.87 24.21 | $86.55 |
| TransMedics | 15.42 13.17 | $132.49 |
| Nutex Health | 12.99 13.09 | $112.19 |
| Insulet | 12.89 3.87 | $346.36 |
| Mettler-Toledo | 7.98 0.57 | $1,404.43 |
| Movano Health | 6.95 223.47 | $10.06 |
| GeneDx | 6.71 5.29 | $133.63 |
| GRAIL | 6.51 7.99 | $87.97 |
| Praxis Precision Medicines | 5.19 2.82 | $189.32 |
| Penumbra | 5.05 1.82 | $283.15 |
| Glaukos | 4.85 5.29 | $96.49 |
| Stryker | 4.71 1.31 | $364.23 |
| Natera | 4.70 2.20 | $218.35 |
| Inhibrx | 4.55 5.86 | $82.14 |
| Bolt Biotherapeutics | 4.12 737.21 | $4.68 |
| Company | Volume | Last Trade |
|---|---|---|
| Zynex | 184,828,483 | $0.55 |
| Kazia Therapeutics | 70,433,678 | $7.90 |
| Pfizer | 59,263,455 | $24.85 |
| Nuvation Bio | 58,743,799 | $7.18 |
| Applied Therapeutics | 49,072,222 | $0.28 |
| Clearmind Medicine | 36,170,765 | $0.20 |
| Agios Pharmaceuticals | 35,301,741 | $22.52 |
| Recursion | 34,235,197 | $4.07 |
| Heron Therapeutics | 30,389,376 | $1.09 |
| Palisade Bio | 30,079,687 | $2.17 |
| Olema Oncology | 29,709,469 | $19.43 |
| Iovance Biotherapeutics | 24,316,250 | $2.26 |
| Exact Sciences | 22,586,576 | $86.55 |
| Quantum-Si | 21,582,078 | $1.28 |
| Geron | 18,749,015 | $1.08 |
| Terns Pharmaceuticals | 17,955,232 | $26.55 |
| Connect Biopharma | 17,850,950 | $3.10 |
| Annexon | 16,711,586 | $4.06 |
| Eledon Pharmaceuticals | 16,324,187 | $1.55 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
